Skip to Content

Basaglar and Lantus - What is the difference between them?

Medically reviewed by Last updated on Nov 5, 2020.

Official Answer


Basaglar is an insulin glargine injection, approved in Dec 2015 and manufactured by Eli Lilly. Basaglar is a "follow-on" product to Lantus (insulin glargine injection), made by Sanofi-Aventis. However, the FDA does not consider Basaglar a biosimilar to Lantus. The FDA did not approve Basaglar as a biosimilar to Lantus because Lantus was not approved under the Public Health Service Act, so there is no “reference product” for a proposed biosimilar product.

They are both long-acting human insulin analogues used for blood glucose (sugar) control in adult and pediatric patients with type 1 diabetes, and in adults with type 2 diabetes.

Basaglar is administered subcutaneously once daily by the KwikPen at the same time every day.

See more with our drug comparison tool:


Related Medical Questions

Drug Information

Related Support Groups